Teva to sell off women’s health businesses for $1.4bn
By 
Phillip Broadwith2017-09-20T13:24:00
Deals continue Teva’s bid to get rid of non-core businesses and raise cash to service its debts
Israeli generics giant Teva has agreed two deals to sell off a portfolio of women’s health products for a total of $1.4 billion (£1 billion) in cash.
Foundation Consumer Healthcare will buy four of Teva’s emergency contraception products for $675 million, while private equity firm CVC Capital Partners will take on medicines for contraception, fertility, menopause and osteoporosis for $703 million.